Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:COLL NASDAQ:ESPR NASDAQ:MRUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$59.58-0.8%$62.92$11.40▼$72.36$1.74B0.79791,512 shs199,686 shsCOLLCollegium Pharmaceutical$34.48+0.8%$34.34$28.34▼$50.79$1.12B0.76500,973 shs93,714 shsESPREsperion Therapeutics$3.14+0.2%$2.54$0.76▼$4.18$807.04M0.918.84 million shs3.33 million shsMRUSMerus$90.00-7.1%$93.01$37.92▼$97.14$6.83B1.061.51 million shs2.73 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+0.52%-4.16%+17.92%+8.33%+184.74%COLLCollegium Pharmaceutical+1.78%-1.86%-0.26%-24.26%+14.22%ESPREsperion Therapeutics0.00%+0.32%+54.95%-11.08%+244.45%MRUSMerus0.00%0.00%0.00%0.00%+104.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$59.58-0.8%$62.92$11.40▼$72.36$1.74B0.79791,512 shs199,686 shsCOLLCollegium Pharmaceutical$34.48+0.8%$34.34$28.34▼$50.79$1.12B0.76500,973 shs93,714 shsESPREsperion Therapeutics$3.14+0.2%$2.54$0.76▼$4.18$807.04M0.918.84 million shs3.33 million shsMRUSMerus$90.00-7.1%$93.01$37.92▼$97.14$6.83B1.061.51 million shs2.73 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+0.52%-4.16%+17.92%+8.33%+184.74%COLLCollegium Pharmaceutical+1.78%-1.86%-0.26%-24.26%+14.22%ESPREsperion Therapeutics0.00%+0.32%+54.95%-11.08%+244.45%MRUSMerus0.00%0.00%0.00%0.00%+104.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.85Moderate Buy$79.1832.90% UpsideCOLLCollegium Pharmaceutical 2.67Moderate Buy$57.5066.76% UpsideESPREsperion Therapeutics 2.00Hold$5.5476.71% UpsideMRUSMerus 2.00Hold$95.936.59% UpsideCurrent Analyst Ratings BreakdownLatest ESPR, COLL, ANAB, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ANABAnaptysBio Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.005/13/2026ANABAnaptysBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026ANABAnaptysBio UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $76.005/13/2026ANABAnaptysBio BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$63.00 ➝ $75.005/4/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/4/2026ANABAnaptysBio Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$95.00 ➝ $93.005/4/2026ESPREsperion Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/1/2026ESPREsperion Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M7.39N/AN/A$0.44 per share135.41COLLCollegium Pharmaceutical$780.57M1.43$15.60 per share2.21$9.63 per share3.58ESPREsperion Therapeutics$403.14M2.00N/AN/A($1.20) per share-2.61MRUSMerus$36.13M188.94N/AN/A$9.46 per share9.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$1.08N/A19.22N/A-11.53%-1,101.24%-7.75%8/5/2026 (Estimated)COLLCollegium Pharmaceutical$62.87M$2.0416.905.83N/A9.41%95.18%16.39%8/6/2026 (Estimated)ESPREsperion Therapeutics-$22.68M-$0.06N/A14.252.540.12%-0.14%0.12%8/4/2026 (Estimated)MRUSMerus-$215.33M-$5.30N/AN/AN/A-673.31%-52.99%-44.61%N/ALatest ESPR, COLL, ANAB, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ANABAnaptysBio-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million5/8/2026Q1 2026ESPREsperion Therapeutics-$0.02-$0.10-$0.08-$0.10$84.52 million$80.10 million5/7/2026Q1 2026COLLCollegium Pharmaceutical$1.52$1.76+$0.24$0.40$184.47 million$193.52 million3/10/2026Q4 2025ESPREsperion Therapeutics$0.23$0.22-$0.01$0.22$165.12 million$168.45 million3/3/2026Q4 2025ANABAnaptysBio$0.89$1.58+$0.69$1.58$87.09 million$108.25 million2/26/2026Q4 2025COLLCollegium Pharmaceutical$2.20$2.04-$0.16$0.46$206.36 million$205.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A7.587.58COLLCollegium Pharmaceutical2.471.711.62ESPREsperion TherapeuticsN/A1.531.18MRUSMerusN/A7.977.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACOLLCollegium PharmaceuticalN/AESPREsperion Therapeutics47.39%MRUSMerus96.14%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%COLLCollegium Pharmaceutical1.85%ESPREsperion Therapeutics1.60%MRUSMerus3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.10 million19.35 millionOptionableCOLLCollegium Pharmaceutical21032.43 million31.83 millionOptionableESPREsperion Therapeutics200257.43 million253.31 millionOptionableMRUSMerus3775.85 million73.04 millionOptionableESPR, COLL, ANAB, and MRUS HeadlinesRecent News About These CompaniesLeonaBio Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comMerus Power Delivers an Energy Storage System for Extreme Arctic ConditionsFebruary 11, 2026 | businesswire.comInsider Buying: Merus (NASDAQ:MRUS) Major Shareholder Purchases 2,978 Shares of StockDecember 31, 2025 | insidertrades.comMerus Completes Genmab Acquisition and Delists From NasdaqDecember 30, 2025 | tipranks.comMerus (NASDAQ:MRUS) Major Shareholder A/S Genmab Purchases 15,710 SharesDecember 30, 2025 | insidertrades.comMerus (NASDAQ:MRUS) Major Shareholder A/S Genmab Purchases 66,264 SharesDecember 23, 2025 | insidertrades.comA/S Genmab Purchases 120,752 Shares of Merus (NASDAQ:MRUS) StockDecember 19, 2025 | insidertrades.comMerus acquired by Genmab, leadership changes announcedDecember 13, 2025 | msn.comGenmab Completes Acquisition of Merus N.V. to Bolster Oncology PortfolioDecember 12, 2025 | tipranks.comGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodDecember 12, 2025 | businesswire.comGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodDecember 12, 2025 | globenewswire.comInsider Selling: Merus (NASDAQ:MRUS) VP Sells 1,700 Shares of StockDecember 11, 2025 | insidertrades.comMerus Shareholders Approve Genmab Acquisition ProposalDecember 9, 2025 | tipranks.comMerus N.V. (MRUS): A Bull Case TheoryDecember 5, 2025 | finance.yahoo.comMerus NV (MRUS): A bull case theoryDecember 4, 2025 | msn.comAssessing Merus (MRUS) Valuation Following Recent Share Price SurgeNovember 30, 2025 | finance.yahoo.comHarry Shuman Sells 8,300 Shares of Merus (NASDAQ:MRUS) StockNovember 29, 2025 | insidertrades.comMerus (MRUS) Gets a Buy from Bank of America SecuritiesNovember 25, 2025 | theglobeandmail.comBarclays Sticks to Its Hold Rating for Merus (MRUS)November 25, 2025 | theglobeandmail.com$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-MRUS, ACLS, VECO, and CLCONovember 21, 2025 | kxan.comKNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026The Trade Desk: Down 75%, But a Reversal May Be NearBy Sam Quirke | April 25, 20265 Reasons Rambus Stock Price Collapse Is One Hot Entry PointBy Thomas Hughes | May 1, 2026The Power Grid Is Dying—Is It Time to Buy Its Replacement?By Jeffrey Neal Johnson | May 15, 2026TMC Forges a New EV Supply Chain at the Bottom of the SeaBy Jeffrey Neal Johnson | May 12, 2026ESPR, COLL, ANAB, and MRUS Company DescriptionsAnaptysBio NASDAQ:ANAB$59.58 -0.50 (-0.83%) As of 02:12 PM Eastern This is a fair market value price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Collegium Pharmaceutical NASDAQ:COLL$34.48 +0.26 (+0.76%) As of 02:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Esperion Therapeutics NASDAQ:ESPR$3.14 +0.01 (+0.16%) As of 02:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Merus NASDAQ:MRUSMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
